Use of ‘FS’ endorsement extended to Tuberculosis (TB) treatments
From 1 December 2025, the use of the ‘FS’ prescriber endorsement has been extended to treatments used in the management of tuberculosis (TB) and latent TB infections, including the effects of TB and the adverse effects from TB treatment. Pharmacy teams should ensure that no prescription charge is levied for any items endorsed ‘FS’ by [...]
The post Use of ‘FS’ endorsement extended to Tuberculosis (TB) treatments appeared first on Community Pharmacy England.
Recent Comments